TECENTRIQ is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Atezolizumab.
Product ID | 50242-918_0db9ee06-7a81-45f8-862b-b84180b9db13 |
NDC | 50242-918 |
Product Type | Human Prescription Drug |
Proprietary Name | TECENTRIQ |
Generic Name | Atezolizumab |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2019-03-08 |
Marketing Category | BLA / BLA |
Application Number | BLA761034 |
Labeler Name | Genentech, Inc. |
Substance Name | ATEZOLIZUMAB |
Active Ingredient Strength | 840 mg/14mL |
Pharm Classes | Programmed Death Receptor-1 Blocking Antibody [EPC],Antibodies, Monoclonal, Humanized [CS],Antibodies, Monoclonal [CS],Antibodies [CS],Programmed Death Receptor-1-directed Antibody Interactions [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2019-03-08 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761034 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2019-03-08 |
Marketing Category | BLA |
Application Number | BLA761034 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2019-03-08 |
Ingredient | Strength |
---|---|
ATEZOLIZUMAB | 840 mg/14mL |
NDC | Brand Name | Generic Name |
---|---|---|
50242-917 | TECENTRIQ | atezolizumab |
50242-918 | TECENTRIQ | atezolizumab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TECENTRIQ 86441478 5027722 Live/Registered |
GENENTECH, INC. 2014-10-31 |